Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + mFOLFOX6 versus standard first-line therapy for HER2-positive metastatic colorectal cancer
NL-OMON56153Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tucatinib, trastuzumab, oxaliplatin, folinic acid, fluorouracil and 2 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON56153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56153.